February 1, 2010 (FinancialWire) — Pharmasset, Inc. (NASDAQ: VRUS) said that the underwriter of its recent stock offering has exercised its option to purchase an additional 230,400 shares of common stock. The net proceeds to Pharmasset from the sale of these additional shares will be around $4.1 million.

This brings the total expected proceeds of the offering, after deducting the underwriting discount and estimated offering expenses, to $32.7 million. Leerink Swann LLC served as sole book-running manager for the offering.

Pharmasset granted the option in connection with its offering of 1.6 million shares of common stock at an offering price of $18.75 per share, which is scheduled to close on February 2, 2010.

New Jersey-based Pharmasset is a clinical-stage pharmaceutical company focused on discovering, developing and commercializing novel drugs to treat viral infections.

Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus and, secondarily, on human immunodeficiency virus.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.